Subscribe
Subscribe today to receive CGD’s latest newsletters and topic updates.
All Commentary
Filters:
Topics
Facet Toggle
Content Type
Facet Toggle
Blog Type
Facet Toggle
Time Frame
Facet Toggle
Blog Post
December 14, 2022
Four new CGD pieces, released today, examine the current state of play on COVID-19 oral antivirals. Our analyses provide a deep-dive in key cross-cutting areas—demand, voluntary licensing deals for generic supply, and deployment—and offer policy actions for 2023 and beyond.
Blog Post
September 14, 2022
In March, the World Bank estimated that a dozen developing countries could default on their debt over the next 12 months. The warning signs are everywhere. Investors have pulled $50 billion from emerging-market bond funds this year, and the debt of nearly one-third of these countries is trading at d...
Blog Post
August 18, 2022
I’ve taken pride over the years in CGD’s success as a think-and-do tank in coming up with new “products” (outcomes of think/research) and working with officials around the world to see them adopted and implemented (outcomes of do/outreach and advocacy)). New products that change people’s lives in go...
Blog Post
August 10, 2022
PEPFAR’s new strategy—to be released in final form later this year—focuses on how to accelerate progress toward epidemic control amidst continued impacts from COVID-19, while also strengthening core health system functions as well as partnership and coordination efforts; this is precisely what the c...